原发性硬化性胆管炎患者基于影像的评分系统的观察者间一致性与预后价值
纳入59例原发性硬化性胆管炎患者,由2名专家独立对MRCP图像进行Anali和Amsterdam评分,评估观察者间一致性和以肝功能失代偿为主要终点的预后表现。Anali和Amsterdam评分的观察者间一致性均为中等(k分别为0.49和0.43)。Anali评分、总胆红素和年龄是肝功能失代偿的独立预测因子,Anali评分在调整Mayo风险评分后仍为独立预测因子。
要点
- Anali评分与Amsterdam评分的观察者间一致性均为中等(k=0.49与k=0.43)。
- Anali评分中肝内胆管扩张一致性较好(k=0.70),形态异常一致性一般(k=0.37)。
- Anali评分是肝功能失代偿的独立预测因子(HR 5.90),调整Mayo风险评分后仍独立。
核心结论
- Anali评分对原发性硬化性胆管炎患者肝功能失代偿具有额外预测价值。
研究设计与样本
- 研究纳入至少接受1次MRCP的原发性硬化性胆管炎患者59例(67.8%男性,86.4%合并炎症性肠病),由2名专家独立对图像进行Anali和Amsterdam评分,评估观察者间一致性和以肝功能失代偿为主要终点的预后表现。
诊断标准与关键数值
- Anali评分观察者间一致性为中等(k=0.49;95%CI 0.35-0.64),Amsterdam评分为中等(k=0.43;95%CI 0.30-0.56)。
- Anali评分中形态异常(尾状叶/右叶比值>0.9)一致性为一般(k=0.37;95%CI 0.14-0.60),门静脉高压一致性为较好(k=0.64;95%CI 0.32-0.89),肝内胆管扩张一致性为较好(k=0.70;95%CI 0.53-0.87)。
- Amsterdam评分肝外部分一致性为一般(k=0.38;95%CI 0.23-0.52),肝内部分一致性为中等(k=0.50;95%CI 0.34-0.67)。
- Anali评分(HR 5.90;95%CI 1.64-21.21)、总胆红素(HR=3.23;95%CI 1.06-9.91)和年龄(HR=1.05;95%CI 1.00-1.11)是肝功能失代偿的独立预测因子。
- Mayo风险评分和Anali评分的区分能力较好,c-statistic分别为0.78(95%CI 0.59-0.96)和0.76(95%CI 0.56-0.91)。
临床应用与阅片要点
- Anali评分可用于原发性硬化性胆管炎患者肝功能失代偿的风险评估,且其预测价值独立于Mayo风险评分。
- Anali评分中形态异常(尾状叶/右叶比值>0.9)的观察者间一致性一般,判读时需注意。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that progresses to cirrhosis and liver failure. The Anali and Amsterdam scores are based upon imaging features on MRI and ERCP, respectively.
AIMS: We aimed to compare the interobserver variability and performances of these scores.
METHODS: Patients with PSC with at least 1 MRCP were included. Images were independently scored by 2 experts. Agreement and prognostic performance with a primary end point of hepatic decompensation was assessed.
RESULTS: Fifty-nine patients were included (67.8% male, 86.4% IBD). Interobserver agreement for the Anali and Amsterdam scores were moderate (k = 0.49; 95% CI 0.35-0.64 and k = 0.43; 95% CI 0.30-0.56, respectively). Among the Anali components, dysmorphy (caudate/right lobe ratio > 0.9) had fair agreement (k = 0.37; 95% CI 0.14-0.60) and portal hypertension (k = 0.64, 95% CI 0.32-0.89) and intrahepatic dilation (k = 0.70; 95% CI 0.53-0.87) had substantial agreement. The Amsterdam extrahepatic and intrahepatic scores had fair agreement (k = 0.38; 95% CI 0.23-0.52) and moderate agreement (k = 0.50; 95% CI 0.34-0.67), respectively. Anali score (HR 5.90, 95% CI 1.64-21.21), total bilirubin (HR = 3.23; 95% Cl 1.06-9.91), and age (HR = 1.05; 95% CI 1.00-1.11) were independent predictors of hepatic decompensation. Mayo risk score and Anali score had good discriminative ability with c-statistics of 0.78 (CI 0.59-0.96) and 0.76 (CI 0.56-0.91). Anali score remained an independent predictor after adjusting for Mayo risk score.
CONCLUSION: Anali score adds additional predictive value for hepatic decompensation in patients with PSC.
引用
- Grave EC, Loehfelm T, Corwin MT, et al. Interobserver agreement and prognostic value of image-based scoring systems in patients with primary sclerosing cholangitis. Abdom Radiol (NY). 2023. PMID: 37831167. doi:10.1007/s00261-023-04051-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。